Compare AbCellera Biologics Inc (ABCL) vs CSX Corporation (CSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs CSX Corporation — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while CSX Corporation trades at $48.2 (market cap $90.14B). The key difference: CSX Corporation is far larger — about 38.4× AbCellera Biologics Inc's market cap, and CSX Corporation pays a 1.15% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | CSX | |
|---|---|---|
Market Cap | $2.35B | $90.14B |
Sector | Health | Industrials |
52-Week High | $8.12 | $48.89 |
52-Week Low | $2.78 | $32.05 |
Enterprise Value | $1.99B | $108.37B |
Dividend Yield | — | 1.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
CSX trades at $48.51, down 0.78% on the day, with a bullish technical outlook from moving averages but neutral oscillators. The company reported a net income margin of 21.55% for 2025, though revenue has declined from $14.9B in 2022 to $14.1B in 2025. Analyst consensus is a Buy with a $46.83 price target, and the stock has seen positive news coverage highlighting operational improvements and a recent dividend declaration.
The outlook for CSX is cautiously optimistic, supported by strong profitability metrics and analyst upgrades, but tempered by declining revenue trends and high valuation multiples. Key risks include freight demand volatility and competitive pressures, while institutional sentiment remains positive with a majority of analysts recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →
